<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234389</url>
  </required_header>
  <id_info>
    <org_study_id>HN-0004</org_study_id>
    <nct_id>NCT01234389</nct_id>
  </id_info>
  <brief_title>Immediate Detection of Helicobacter Infection With a New Electrochemical System.</brief_title>
  <official_title>Immediate Detection of Helicobacter Infection With a New Electrochemical System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-N端rnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-N端rnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori-infection (H. pylori) affects about fifty percent of the general&#xD;
      population and is associated with peptic ulcer disease, non-cardia gastric adenocarcinoma and&#xD;
      gastric lymphoma. Currently, diagnostic methods include breath tests, serology, stool antigen&#xD;
      tests, histology or the Helicobacter urease test (HUT).&#xD;
&#xD;
      The aim of our study is to access the clinical reliability of a new, electrochemical device&#xD;
      for rapid H. pylori detection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The newly developed electrochemical device for H. pylori detection consists of a working and&#xD;
      reference electrode between which a biopsy sample is administered. Afterwards, acquired&#xD;
      voltage-values could be analysed for characteristics typical for H. pylori infection&#xD;
      (ammonia). According to Sydney classification, biopsies are taken from gastric antrum and&#xD;
      corpus for electrochemical H. pylori detection, HUT and immunohistochemistry (IHC). HUT&#xD;
      results are evaluated after 24 hours. Furthermore, every patient will receive 13C-urea breath&#xD;
      test. IHC is designated as the gold standard of H. pylori diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of the newly developed device in comparison to IHC, HUT and C13-urea breath test.</measure>
    <time_frame>Oktober 2009 - February 2011</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>H. Pylori Infection</condition>
  <arm_group>
    <arm_group_label>H. pylori positive patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>H. pylori negative patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrochemical H. pylori detection method</intervention_name>
    <description>Determination of H. pylori infection.</description>
    <arm_group_label>H. pylori negative patients</arm_group_label>
    <arm_group_label>H. pylori positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IHC</intervention_name>
    <description>Determination of H. pylori infection.</description>
    <arm_group_label>H. pylori negative patients</arm_group_label>
    <arm_group_label>H. pylori positive patients</arm_group_label>
    <other_name>Determination of H. pylori infection.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>C13-urea breath test</intervention_name>
    <description>Determination of H. pylori infection.</description>
    <arm_group_label>H. pylori negative patients</arm_group_label>
    <arm_group_label>H. pylori positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HUT</intervention_name>
    <description>Determination of H. pylori infection.</description>
    <arm_group_label>H. pylori negative patients</arm_group_label>
    <arm_group_label>H. pylori positive patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age 18-85 years&#xD;
&#xD;
          -  Ability of subjects to understand character and individual consequences of clinical&#xD;
             trial&#xD;
&#xD;
          -  Subjects undergoing EGD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Severe Coagulopathy (Prothrombin time &lt; 50% of control, Partial thromboplastin time &gt;&#xD;
             50 s)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Active gastrointestinal bleeding&#xD;
&#xD;
          -  Residing in institutions (e.g. prison)&#xD;
&#xD;
          -  PPI intake&#xD;
&#xD;
          -  antibiotic use, actual or within the last 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus F. Neurath, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Erlangen-N端rnberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helmut Neumann, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-N端rnberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Erlangen-Nuremberg</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

